id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-2077-0007,FDA,FDA-2025-P-2077,Response Letter,Other,Letter(s),2025-12-31T05:00:00Z,2025,12,2025-12-31T05:00:00Z,,2025-12-31T19:22:07Z,,0,0,09000064b9111c53
FDA-2025-P-2077-0006,FDA,FDA-2025-P-2077,Completeness Assessment Correspondence,Other,Assessment Document or Analysis,2025-07-16T04:00:00Z,2025,7,2025-07-16T04:00:00Z,,2025-07-16T18:34:06Z,,0,0,09000064b8e77d29
FDA-2025-P-2077-0002,FDA,FDA-2025-P-2077,Acknowledgment Letter from FDA DMB to Premier Research,Other,Acknowledgement Letter/Receipt,2025-07-01T04:00:00Z,2025,7,2025-07-01T04:00:00Z,,2025-07-01T19:56:25Z,,0,0,09000064b8e4b993
FDA-2025-P-2077-0001,FDA,FDA-2025-P-2077,Suitability Petition from Premier Research,Other,Petition(s),2025-07-01T04:00:00Z,2025,7,2025-07-01T04:00:00Z,,2026-02-27T01:30:38Z,,0,0,09000064b8e4b990
FDA-2025-P-2077-0003,FDA,FDA-2025-P-2077,Appendix 1 - Approved Product Labeling - Prozac,Supporting & Related Material,Background Material,2025-07-01T04:00:00Z,2025,7,,,2025-07-01T19:56:35Z,,0,0,09000064b8e4bd79
FDA-2025-P-2077-0004,FDA,FDA-2025-P-2077,Appendix 2 - FDA Orange Book - Prozac,Supporting & Related Material,Background Material,2025-07-01T04:00:00Z,2025,7,,,2025-07-01T19:56:45Z,,0,0,09000064b8e4bd7a
FDA-2025-P-2077-0005,FDA,FDA-2025-P-2077,Appendix 3 - Proposed Draft Labeling for the Fluoxetine Hydrochloride Capsules,Supporting & Related Material,Background Material,2025-07-01T04:00:00Z,2025,7,,,2025-07-01T19:56:53Z,,0,0,09000064b8e4bd7b